Clinical trial registry record

A Prospective Non-interventional Study to Evaluate Clinical Outcomes of Ribociclib Combined With Endocrine Therapy in Elderly Patients With HR+HER2 - Advanced Breast Cancer in Routine Clinical Practice in Russian Federation

A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Active Not Recruiting.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 1, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06625333
Last registry update
April 1, 2026
Status
Active Not Recruiting
Phase
Phase not reported
Sponsor
Novartis Pharmaceuticals
Enrollment
329
Countries
Russia
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
329
Population
ALL · 65 Years to 99 Years
Duration
2024-10-11 to 2027-12-31
Intervention
Comparator
Not reported
Outcomes measured
change of QoL (RAND SF-36) — from baseline to the level at 12 months; Time to treatment failure (TTF) — up to two years; Progression free survival rate (PFS) — up to two years; Median progression free survival — up tp two years; Overall survival rate (OS) — up to two years; Objective response rate (ORR) — up to two years; Clinical benefit rate (CBR) — up to two years; Proportions (%) of patients and reasons of permanent discontinuation of ribociclib — up to two years; Proportions (%) of patients and reasons of dose adjustment on ribocicli — up to two years; Adverse events (AEs) frequency and severity — up to two years; Quality of life (RAND SF-36, questionnaire of patient's satisfaction) — up to two years
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Cancer and ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

cancer and aging
Read the original source →Export JSON